Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Tafamidis attenuates the decline of cardiac function in transthyretin amyloid cardiomyopathy
Challenges with Diversity in Clinical Trials
Vision for 2024: Growing with Heart
Cancer Stories: The Art of Oncology
FDA approves Wainua for polyneuropathy of hereditary transthyretin-mediated amyloidosis
"Tomorrow, is the first blank page of a 365-page book. Write a good one." – Brad Paisley
A Mosaic of Milestones
Celebrating a Year of Impactful Connections and Looking Ahead
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Tafamidis attenuates the decline of cardiac function in transthyretin amyloid cardiomyopathy
Challenges with Diversity in Clinical Trials
Vision for 2024: Growing with Heart
Cancer Stories: The Art of Oncology
FDA approves Wainua for polyneuropathy of hereditary transthyretin-mediated amyloidosis
"Tomorrow, is the first blank page of a 365-page book. Write a good one." – Brad Paisley
A Mosaic of Milestones
Celebrating a Year of Impactful Connections and Looking Ahead
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
